TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically established ADPKD~* eGFR\>30ml/min.~* Chinese nationality~Exclusion Criteria:~* Uncontrolled infections~* Non-ADPKD complications

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- emodin (Type: ACTIVE_COMPARATOR): None
- Triptolide Woldifii (Type: EXPERIMENTAL): TW60mg/d

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Dose Conversion Study of Epoetin Alfa in Subjects With the Anemia of Chronic Kidney Disease.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with chronic kidney disease defined as serum creatinine of 1.5 to 6.0 mg/dL for women and 2.0 to 6.0 mg/dL for men~* glomerular filtration rate (GFR) within 15-60 mL/min~* Subjects on darbepoetin alfa for 3 months or more and with a stable entry hemoglobin level of 12 (plus or minus 1 g/dL~* range 11-13 g/dL)~* Subjects receiving darbepoetin alfa on an every two, three, or four week dosing schedule~* female subjects with a reproductive potential must have a negative ruine pregnancy test within 7days of the first dose of study drug.~Exclusion Criteria:~* No uncontrolled high blood pressure as assessed by the primary physician~* No known hypersensitivity to mammalian cell-derived products~* No known hypersensitivity to human albumin~* Not receiving dialysis or scheduled to receive dialysis during the course of the study~* No severe congestive heart failure (New York Heart Association Class IV)~* No known severe stable or unstable coronary artery disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of both genders (females and males) over 18 years of age~* Written informed consent obtained from the subjects prior to any procedures related to the study~* Understand all procedures to be applied within the scope of the study protocol~* Ambulatory patients with symptoms diagnosed with COVID-19 with Chest tomography (CT) result positivity in the last 72 hours~* Patients with stable clinical course and who could be treated on an ambulatory basis.~Exclusion Criteria:~* Patients who has partial oxygen saturation below 93% and require immediate hospitalisation after diagnosis~* Patients, upon initial examination, decided to be hospitalised at the intensive care-unit~* Inability or unwillingness to give written informed consent~* At physicians decision, the trial involvement will not be in patients' best interest, or any condition that does not allow the protocol to be followed safely~* Patients considered as inappropriate for this study for any reason~* Active participation in another clinical study~* Uncontrolled Type 1 or type 2 diabetes~* Severe liver disease (e.g. Child Pugh score ≥ C, AST\>5 times upper limit)~* Patients with known severe renal impairment (estimated glomerular filtration rate ≤30 mL/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis~* Significant cardiovascular co-morbidity (i.e. heart failure)~* Patients with phenylketonuria (contraindicated for NAC)~* Known allergy for substances used in the study~* Pregnant or breastfeeding patients, or patients with positive pregnancy test in a pre-dose examination~* Receipt of any experimental treatment for COVID-19 within the 30 days prior to the time of the screening evaluation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Subjects in ambulatory-at home-treatment will receive hydroxychloroquine (standard therapy) + dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside.
- Placebo Arm (Type: PLACEBO_COMPARATOR): Subjects will take hydroxychloroquine (standard therapy) + dietary supplement placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years of age~* Confirmed COVID-19 infection by presence of SARS-CoV-2 nucleic acid by polymerase chain reaction (PCR)~* Evidence of pneumonia given by at least one of the following: SpO2 ≤93% on ambient air or PaO2/FiO2 \<300 mmHg/40 kPa OR Radiographic findings compatible with COVID-19 pneumonia~* For women of childbearing potential: Negative pregnancy test and willingness to use contraceptive (consistent with local regulations) during study period~* Signed Informed Consent Form by any patient capable of giving consent, or, when the patient is not capable of giving consent, by his or her legal/authorized representatives~Exclusion Criteria:~* In the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatment~* Participating in other drug clinical trials (participation in COVID-19 antiviral trials may be permitted if approved by sponsor)\*~* Pregnant or breastfeeding, positive pregnancy test in a pre-dose examination~* Any serious medical condition or abnormality of clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Convalescent plasma (Type: ACTIVE_COMPARATOR): Will receive active treatment with convalescent anti-SARS-CoV-2 plasma (600 ml) as a single dose iv infusion in addition to standard care.
- Infusion placebo (Type: PLACEBO_COMPARATOR): Will receive placebo treatment with saline 0.9% (2 x 300 ml) as an iv single dose infusion in addition to standard care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Antibiotics Versus Placebo in the Treatment of Abscesses in the Emergency Department

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 3 months to 17 years~* Single, localized soft tissue abscesses requiring incision and drainage with purulent material obtained~* Diameter of the abscess less than 5cm as measured by the treating physician~Exclusion Criteria:~* Signs of systemic illness or ill-appearing, as determined by the treating physician~* Admission to the hospital following treatment in the Emergency Department~* Known sulfa allergy~* Immunocompromised patients~* Soft tissue abscesses involving the perineum (labia, scrotum, penis, perirectal)~* Previous antibiotic use (for any reason) in the past seven days~* Non-English speaking patients and families

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Trimethoprim-sulfamethaxazole (Type: EXPERIMENTAL): Incision and drainage of the abscess and treatment with oral TMP-SMX (100 patients)
- Sugar pill (Type: PLACEBO_COMPARATOR): Incision and drainage of the abscess and treatment with oral placebo (100 patients)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Reduction of Dust Mite Allergenic Load on Step Down of Inhaled Corticosteroids in Stable Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* confirmed asthma diagnosis~* controlled asthma for more than 3 months~* treatment with inhaled corticosteroids~* dust mite allergy proved by skin tests ou specific immunoglobulin E~Exclusion Criteria:~* chronic obstructive pulmonary disease, bronchiectasis, Fibrosis, tuberculosis~* asthma-chronic obstructive pulmonary disease overlap syndrome~* ongoing desensitization for dust mite~* pregnancy~* previous use of Acar'up

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- control group (Type: PLACEBO_COMPARATOR): stable asthmatics receiving an Acar'up placebo system
- treatment group (Type: ACTIVE_COMPARATOR): stable asthmatics receiving Acar'up system

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female patients 18 years of age or older~2. Karnofsky Performance Status (KPS) of 70 or higher~3. Capable of giving informed consent or have an acceptable surrogate capable of giving consent of the subject's behalf~4. Have a documented history of HER2/neu positive breast cancer that is 3+ on immunohistochemical staining or positive on fluorescent in-situ hybridization (FISH) or chromogenic in-situ hybridization (CISH) and have evidence of parenchymal metastatic tumor(s) on brain imaging studies.~5. Adequate labs for procedure with trastuzumab, including but not limited to White Blood Count (WBC), Hemoglobin, Hematocrit, Platelet Count, Prothrombin Time (PT), International Normalized Ratio (INR), Sodium, Potassium, Chloride, Glucose, Blood Urea Nitrogen (BUN), Serum Creatinine (CR)~Exclusion Criteria:~1. Age less than 18 years~2. KPS less than 70~3. Brain metastases without history of HER2/neu positive breast cancer~4. Leptomeningeal dissemination of brain metastases~5. Pregnancy or refusal to use contraception during a 3 month period before and 7 month period after Intra-arterial (IA) trastuzumab administration~6. Prior administration of intraarterial trastuzumab~7. Subjects with inadequate baseline Left Ventricular Ejection Fraction (LVEF)~8. Subjects with history of infusion reaction with trastuzumab~9. Subjects who have had blood brain barrier (BBB) disruption with mannitol within 48 hours~10. Subjects with evidence of midline shift or herniation~11. Subjects with resectable brain metastases or whose cerebral tumors are amenable to stereotactic radio-surgery~12. Subjects who have not progressed after therapy for brain metastases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intra-arterial Cerebral Infusion of Trastuzumab (Type: EXPERIMENTAL): Super-selective Intra-arterial Cerebral Infusion of Trastuzumab After Blood-Brain Barrier Disruption

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Neuromodulation of Inflammation and Vascular Function in Systolic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients (18 years or older) with Heart failure with reduced ejection fraction (HFrEF), which is a history of symptomatic heart failure with left ventricular ejection fraction (LVEF) of \< 40%.~Exclusion Criteria:~1. Patients in overt congestive heart failure / recent acute myocardial infarction (\< 3 months) or Unstable angina~2. Active malignancy~3. Pre-menopausal women and post-menopausal women on hormone supplements.~4. Unilateral or bilateral vagotomy~5. Patients with bilateral upper extremity amputation~6. Pregnant patients~7. End-stage renal disease~8. End-stage liver disease~9. History of recurrent vasovagal syncope, Sick sinus syndrome, 2nd- or 3rd-degree atrioventricular (AV) block.~10. Patients with clinically documented upper extremity arterial disease~11. Patients with a body mass index (BMI) \>35~12. Significant hypotension (blood pressure \<90mmHg) secondary to autonomic dysfunction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 4 weeks.
- CONTROL (Type: SHAM_COMPARATOR): Sham TVS will be performed by use of a Tragus stimulator device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour daily for 4weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the esophagus that is unlikely to respond to existing therapy and for which no curative therapy exists~* Meets 1 of the following criteria:~  * Metastatic disease~ * Not curable with surgery or radiotherapy~* Measurable disease by MRI or CT scan~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2000/mm3~* Platelet count at least 50,000/mm3~Hepatic:~* No hepatic failure~* Bilirubin no greater than 2.5 mg/dL~* SGOT and SGPT no greater than 5 times upper limit of normal~Renal:~* Creatinine no greater than 2.5 mg/ml~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No chronic or congestive heart failure~* No uncontrolled hypertension~* No other cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No serious lung disease, such as severe chronic obstructive pulmonary disease~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No medical illness, psychiatric illness, or non-malignant systemic disease that would preclude study treatment~* No active infection~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~Endocrine therapy:~* Concurrent steroids allowed~Radiotherapy:~* At least 8 weeks since prior radiotherapy (except in patients with multiple tumors who have received radiotherapy to some of their tumors) and recovered~Surgery:~* Recovered from prior surgery~Other:~* No prior antineoplaston therapy~* Prior cytodifferentiating agents allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Registry to Evaluate the Flexitouch System and Flexitouch Plus for Treatment of Head and Neck Lymphedema

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* A diagnosis of head and/or neck lymphedema~* Must be able and willing to participate in all aspects of the registry and provide informed consent prior to registry participation~* Head and chest measurements within the following:~* Crown of head circumference: ≤ 72 cm~* Chest circumference: ≤ 158 cm~* Prescribed the Flexitouch system or Flexitouch Plus~Exclusion Criteria:~* Uncontrolled hyperthyroidism or parathyroidism (for which endocrinologist recommends against neck compression)~* Carotid sinus hypersensitivity syndrome~* Symptomatic carotid artery disease, as manifested by a recent transient ischemic attack (within 30 days), ischemic stroke, or amaurosis fugax (monocular visual ischemic symptoms or blindness)~* Symptomatic bradycardia in the absence of a pacemaker~* Internal jugular venous thrombosis (within 3 months)~* Increased intracranial pressure or other contraindications to internal or external jugular venous compression~* Acute radiation dermatitis, unhealed surgical scar, unhealed or open wound(s), or surgical flap less than 6-8 weeks post-operative~* Facial or head and neck dermal metastasis~* Acute facial infection (e.g., facial or parotid gland abscess)~* Any condition in which increased venous and lymphatic return is undesirable~* Heart failure (acute pulmonary edema, decompensated acute heart failure)~* Subject is pregnant or trying to become pregnant~* Acute venous disease (acute thrombophlebitis, acute deep venous thrombosis, acute pulmonary embolism)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ATG Versus Basiliximab in Kidney Transplant Displaying Low Immunological Risk But High Susceptibility to DGF

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults~* First kidney transplantation~* No anti HLA immunization prior transplantation~* A risk of DGF higher than 40% calculated by the score DGFS (DGFS \>= 0.4)~* Written informed consent~Exclusion Criteria:~* Previous or combined other transplantations~* Non heart beating donors~* Living donors~* Pre-emptive transplantation~* Patients on peritoneal dialysis~* Leucopenia lower than 3000/mm3~* Thrombopenia lower than 100 000/mm3~* Donor EBV positive / recipient EBV Negative~* Pregnant or lactating women~* Patients under guardianship~* Previous and current history of cancer and/or lymphoma~* Current history of HCV or HBV or HIV infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ATG (Type: EXPERIMENTAL): The first infusion of Thymoglobuline® begins before the kidney reperfusion. In case of a patient with a functional arteriovenous fistula or a high-flow venous catheter, the infusion of Thymoglobuline® can begin just after the randomization pre operatively. When the patient has no available arteriovenous fistula for the Thymoglobuline® infusion, it is necessary to install a high-flow vein (central vein) by the anesthesiologist, and to begin the perfusion as soon as possible intra-operatively before the reperfusion of the kidney. The dose of Thymoglobuline® per infusion is 1.5mg/kg. The duration of each infusion is between 6 to 24 hours.~The total duration of the Thymoglobuline® administration is 4 days (starting at and including the first day of the surgery).
- Basiliximab (Type: ACTIVE_COMPARATOR): The first infusion of Simulect® begins within the two hours before the surgery. There is no need of central venous catheter or arteriovenous fistula to infuse the Simulect®. The duration of the infusion is 30 minutes. Each dose of Simulect® is 20 mg. The first infusion of Simulect® is displayed on Day 0 (within the two hours before the surgery) and the second infusion 3 days afterward (Day 4).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues